FOSTER L B CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FOSTER L B CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $536.38M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $483.51M | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $624.52M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $607.19M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $597.96M | Mar 1, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.75M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $118.06M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $112.04M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $89.61M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $86.30M | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | $21.69M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $22.06M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $28.14M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $23.12M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $28.20M | Mar 3, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.55M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $42.95M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.46M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($45.56M) | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.63M | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | $2.10M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $6.83M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $523.0K | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | ($1.87M) | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $26.25M | Mar 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.89M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $20.51M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $9.11M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($7.21M) | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.47M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $15.63M | Mar 2, 2022 |
| FY2019 | Dec 31, 2019 | $36.51M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $38.91M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $28.60M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($134.17M) | Feb 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.83M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $2.56M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $2.22M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.23M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $2.64M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $2.61M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $2.65M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $2.24M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $3.51M | Feb 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.56M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $96.40M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $97.62M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $82.66M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $76.00M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $73.64M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $82.52M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $82.75M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $80.52M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $85.98M | Feb 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.62M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $22.63M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $36.96M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($10.58M) | Nov 1, 2024 |
| FY2019 | Dec 31, 2019 | $29.30M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $25.96M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $39.37M | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.42M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $9.79M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $4.51M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $7.63M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.62M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $9.18M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $6.03M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $3.66M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $6.15M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $7.66M | Feb 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $330.37M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $334.55M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $312.40M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $365.31M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $342.60M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $370.40M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $405.17M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $383.25M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $401.74M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $393.02M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.28M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $178.32M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $142.11M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $137.18M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $183.09M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $176.83M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $169.86M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $122.12M | Mar 3, 2021 |
| FY2020 | Dec 31, 2017 | $154.50M | Mar 3, 2021 |
| FY2018 | Jan 1, 2017 | $140.02M | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.06M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $31.91M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $32.59M | Mar 7, 2025 |
| FY2024 | Dec 31, 2022 | $30.73M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $20.15M | Nov 1, 2024 |
| FY2022 | Dec 31, 2020 | $20.34M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $19.57M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $19.26M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $19.79M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $18.93M | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.12M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $167.58M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $124.63M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $123.17M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $168.73M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $165.11M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $157.53M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $114.32M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $145.80M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $133.67M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.35M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.45M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $2.56M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $2.88M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.37M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $7.56M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $14.18M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $10.28M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $37.68M | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $30.36M | Mar 18, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Mar 3, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Mar 3, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.14M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 10.57M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 10.73M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 10.78M | Nov 1, 2024 |
| FY2022 | Dec 31, 2021 | 10.67M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 10.56M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 10.42M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 10.37M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 10.34M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 10.31M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.24M | Feb 28, 2018 |
| FY2017 | Dec 31, 2015 | $1.66M | Feb 28, 2018 |
| FY2016 | Dec 31, 2014 | $1.35M | Mar 8, 2017 |
| FY2015 | Dec 31, 2013 | $1.24M | Mar 1, 2016 |
| FY2014 | Dec 31, 2012 | $1.03M | Mar 3, 2015 |
| FY2013 | Dec 31, 2011 | $1.02M | Feb 27, 2014 |
| FY2011 | Dec 31, 2010 | $0 | Mar 15, 2012 |
| FY2011 | Dec 31, 2009 | $0 | Mar 15, 2012 |